MA52625A - Lipides cationiques de ribose - Google Patents
Lipides cationiques de riboseInfo
- Publication number
- MA52625A MA52625A MA052625A MA52625A MA52625A MA 52625 A MA52625 A MA 52625A MA 052625 A MA052625 A MA 052625A MA 52625 A MA52625 A MA 52625A MA 52625 A MA52625 A MA 52625A
- Authority
- MA
- Morocco
- Prior art keywords
- ribose
- cationic fat
- cationic
- fat
- ribose cationic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672194P | 2018-05-16 | 2018-05-16 | |
| US201862740095P | 2018-10-02 | 2018-10-02 | |
| US201862749442P | 2018-10-23 | 2018-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52625A true MA52625A (fr) | 2021-03-24 |
Family
ID=66691019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052625A MA52625A (fr) | 2018-05-16 | 2019-05-15 | Lipides cationiques de ribose |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11964051B2 (fr) |
| EP (1) | EP3794008A1 (fr) |
| JP (2) | JP7384832B2 (fr) |
| CN (1) | CN112384523B (fr) |
| AU (1) | AU2019271215B2 (fr) |
| CA (1) | CA3100218A1 (fr) |
| MA (1) | MA52625A (fr) |
| WO (1) | WO2019222424A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853377B2 (en) * | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| EP3793689A1 (fr) * | 2018-05-15 | 2021-03-24 | Translate Bio, Inc. | Administration sous-cutanée d'arn messager |
| EP3986452A1 (fr) | 2019-06-18 | 2022-04-27 | CureVac AG | Vaccin à arnm rotavirus |
| CA3146369A1 (fr) | 2019-07-08 | 2021-01-14 | Translate Bio, Inc. | Nanoparticules lipidiques chargees d'arn messager ameliorees et leurs procedes de fabrication |
| WO2021142245A1 (fr) | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Composés, compositions pharmaceutiques et méthodes pour moduler l'expression de la muc5b dans des cellules et des tissus pulmonaires |
| DE202021004130U1 (de) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN115427021A (zh) | 2020-02-25 | 2022-12-02 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
| AU2021269042A1 (en) | 2020-05-07 | 2023-02-02 | Translate Bio, Inc. | Optimized nucleotide sequences encoding SARS-CoV-2 antigens |
| WO2021226468A1 (fr) | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Compositions améliorées de thérapie par arnm de la cftr |
| WO2021239880A1 (fr) | 2020-05-29 | 2021-12-02 | Curevac Ag | Vaccins combinés à base d'acide nucléique |
| EP4172194A1 (fr) | 2020-07-31 | 2023-05-03 | CureVac SE | Mélanges d'anticorps codés par des acides nucléiques |
| WO2022043551A2 (fr) | 2020-08-31 | 2022-03-03 | Curevac Ag | Vaccins contre le coronavirus à base d'acides nucléiques multivalents |
| CA3194863A1 (fr) | 2020-10-06 | 2022-04-14 | Shrirang KARVE | Procede ameliore et formulation de nanoparticules lipidiques |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| CA3170747A1 (fr) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Procede de reduction des proprietes immunostimulatrices d'arn transcrit in vitro |
| US20250268994A1 (en) | 2021-03-25 | 2025-08-28 | Translate Bio, Inc. | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof |
| EP4312988A2 (fr) | 2021-03-31 | 2024-02-07 | CureVac SE | Seringues contenant des compositions pharmaceutiques comprenant de l'arn |
| CA3215606A1 (fr) * | 2021-04-19 | 2022-10-27 | Shrirang KARVE | Compositions ameliorees pour l'administration d'arnm |
| CA3171589A1 (fr) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Sequence d'acide nucleique amelioree pour l'expression specifique de type cellulaire |
| EP4763287A2 (fr) | 2021-09-03 | 2026-06-24 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| EP4422698A1 (fr) | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| EP4469091A1 (fr) | 2022-01-28 | 2024-12-04 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| CA3248209A1 (fr) | 2022-05-25 | 2023-11-30 | CureVac SE | Vaccin à base d’acide nucléique codant pour un polypeptide antigénique fimh d’escherichia coli |
| WO2024089638A1 (fr) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique |
| AU2023394992A1 (en) | 2022-12-15 | 2025-07-31 | Sanofi Pasteur Inc. | Mrna encoding influenza virus-like particle |
| TW202438514A (zh) | 2022-12-20 | 2024-10-01 | 法商賽諾菲公司 | 鼻病毒mrna疫苗 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
| EP4719352A1 (fr) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Formulations et compositions de nanoparticules lipidiques |
| WO2026008743A1 (fr) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Polymère polyanionique soluble dans l'eau en tant qu'adjuvant pour acide nucléique formulé par un support |
| WO2026033123A1 (fr) | 2024-08-08 | 2026-02-12 | Sanofi Pasteur Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| FR2764304B1 (fr) * | 1997-06-06 | 1999-07-16 | Rhone Poulenc Rorer Sa | Nouvelle classe d'agents transfectants cationiques des acides nucleiques |
| EP1015465A2 (fr) * | 1997-09-08 | 2000-07-05 | Valentis Inc. | Derives de glycosylamine hydrophobes, compositions a base de ces derives et procedes d'utilisation |
| US6696081B2 (en) * | 2000-06-09 | 2004-02-24 | Duke University | Carbohydrate based lipid compositions and supramolecular structures comprising same |
| US20030175966A1 (en) * | 2002-03-14 | 2003-09-18 | Genteric, Inc. | Cationic sugar derivatives for gene transfer |
| JP2004231622A (ja) * | 2003-02-03 | 2004-08-19 | Fuji Photo Film Co Ltd | ヨードアリール基を有するペントース誘導体 |
| CA2569664C (fr) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Arn interferant encapsule dans des lipides |
| DE602007004463D1 (de) * | 2006-03-01 | 2010-03-11 | Nippon Shinyaku Co Ltd | Galactosederivat, arzneimittelträger und medizinische zusammensetzung |
| EP2049665A2 (fr) | 2006-07-28 | 2009-04-22 | Applera Corporation | ANALOGUES DE COIFFES DE NUCLÉOTIDE D'ARNm |
| WO2009058911A2 (fr) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Préparation et isolement d'un arnm coiffé en 5' |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010053572A2 (fr) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Lipidoïdes aminoalcool et leurs utilisations |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| KR101187064B1 (ko) * | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| EP4074693A1 (fr) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Lipides clivables |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| BR112014024131A2 (pt) * | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| US10266559B2 (en) | 2013-03-14 | 2019-04-23 | Translate Bio, Inc. | Ribonucleic acids with 4′-thio-modified nucleotides and related methods |
| HRP20220070T1 (hr) * | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| CN105985386B (zh) * | 2015-02-11 | 2018-06-26 | 大连民族学院 | 一类蔗糖酯型阳离子基因载体及其制备方法 |
| US20180153822A1 (en) | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| JP7256824B2 (ja) | 2018-04-25 | 2023-04-12 | エスリス ゲーエムベーハー | 粒子状製剤用の凍結保護剤 |
-
2019
- 2019-05-15 AU AU2019271215A patent/AU2019271215B2/en active Active
- 2019-05-15 JP JP2020563906A patent/JP7384832B2/ja active Active
- 2019-05-15 WO PCT/US2019/032522 patent/WO2019222424A1/fr not_active Ceased
- 2019-05-15 MA MA052625A patent/MA52625A/fr unknown
- 2019-05-15 CA CA3100218A patent/CA3100218A1/fr active Pending
- 2019-05-15 CN CN201980044653.0A patent/CN112384523B/zh active Active
- 2019-05-15 US US17/054,886 patent/US11964051B2/en active Active
- 2019-05-15 EP EP19728235.3A patent/EP3794008A1/fr active Pending
-
2023
- 2023-11-09 JP JP2023191456A patent/JP2023184713A/ja active Pending
-
2024
- 2024-03-19 US US18/609,160 patent/US20240374521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3794008A1 (fr) | 2021-03-24 |
| JP2023184713A (ja) | 2023-12-28 |
| AU2019271215B2 (en) | 2024-09-12 |
| AU2019271215A1 (en) | 2020-12-03 |
| JP7384832B2 (ja) | 2023-11-21 |
| WO2019222424A1 (fr) | 2019-11-21 |
| CN112384523B (zh) | 2025-03-14 |
| US20240374521A1 (en) | 2024-11-14 |
| US20220323355A1 (en) | 2022-10-13 |
| CN112384523A (zh) | 2021-02-19 |
| US11964051B2 (en) | 2024-04-23 |
| CA3100218A1 (fr) | 2019-11-21 |
| JP2021523184A (ja) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52766A (fr) | Lipides cationiques vitaminiques | |
| EP3733641A4 (fr) | Lipides cationiques | |
| EP3897631A4 (fr) | Dégradation ciblée de protéines | |
| EP3589662A4 (fr) | Protéine monovalente inductible de fixation d' antigène | |
| DK3835287T3 (da) | Kationisk lipid | |
| DK3794042T5 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| EP3876986A4 (fr) | Immunotolérance ciblée | |
| EP3765267A4 (fr) | Impression en trois dimensions | |
| EP3792900A4 (fr) | Simulateur de technique | |
| CL2018002038S1 (es) | Cultivador | |
| EP3609527A4 (fr) | Conjugués de protéines | |
| EP3897163A4 (fr) | Injecteur à viande | |
| EP3781109A4 (fr) | Support de genou | |
| EP3976219C0 (fr) | Unité de récupération de graisse | |
| DK3817981T3 (da) | Pølsebakke | |
| EP3724212A4 (fr) | Expression de protéine crm197 | |
| MA50025A (fr) | Nucléosides de spirothiétane | |
| EP3727404A4 (fr) | Combinaisons de lipides | |
| EP3784475A4 (fr) | Impression tridimensionnelle | |
| UA41948S (uk) | Сосиска | |
| UA40369S (uk) | Обігрівач масляний | |
| UA40394S (uk) | Обігрівач масляний | |
| UA40391S (uk) | Обігрівач масляний | |
| ES1229406Y (es) | Embutido | |
| PL3752782T3 (pl) | Podgrzewacz |